Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission

NCT00522301 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions

DRUG: sorafenib tosylate
OTHER: immunoenzyme technique
OTHER: immunohistochemistry staining method
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]